Cryoport, Inc. today introduced the MVE Fusion 800 Series, a self‑sustaining cryogenic freezer that eliminates the need for a continuous liquid‑nitrogen supply. The 32‑inch‑wide unit can be moved through standard doorways and delivers storage temperatures at or below –150 °C, enabling laboratories and hospital pharmacies to adopt true cryogenic storage without costly facility modifications.
The Fusion 800 builds on Cryoport’s award‑winning Fusion platform and was honored with the ISBER Outstanding New Product Award, underscoring its technical innovation. CEO Jerrell Shelton said the freezer “solves a longstanding challenge in cryogenic storage by protecting critical biological materials without the space and infrastructure requirements of legacy systems,” positioning it as a potential new standard for research facilities, biorepositories, and clinical sites worldwide.
By adding a high‑density, low‑space cryogenic solution, Cryoport expands its portfolio beyond logistics and cryopreservation services. The new hardware line opens a distinct revenue stream that complements the company’s existing life‑sciences services and strengthens its position in the regenerative‑medicine supply chain.
Cryoport’s recent financial results reinforce the strategic timing of the launch. In the third quarter, the company reported revenue of $44.2 million, up 15 % year‑over‑year, and beat analyst estimates. The company also raised its fiscal‑2025 revenue guidance to $170‑$174 million, reflecting confidence in continued demand for its expanded product and service offerings.
The Fusion 800’s compact, self‑sustaining design addresses a critical pain point for many potential customers: the need for large, LN2‑dependent freezers that require dedicated infrastructure. By removing that dependency, Cryoport lowers the barrier to entry for smaller facilities and positions the product as a scalable solution for the growing cell‑ and gene‑therapy market.
Overall, the launch signals Cryoport’s intent to deepen its hardware footprint while leveraging its logistics expertise, creating a more integrated end‑to‑end supply‑chain solution for regenerative‑medicine stakeholders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.